GW1929
| Code | Size | Price |
|---|
| AG-CR1-0116-M001 | 1 mg | £45.00 |
Quantity:
| AG-CR1-0116-M005 | 5 mg | £115.00 |
Quantity:
| AG-CR1-0116-M025 | 25 mg | £425.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma Agonist; (2S)-((2-Benzoylphenyl)amino-3-[4-[2-(methylpyridin-2-ylamino)ethoxy]phenyl]propionic acid
Appearance:
Off-white to yellow crystalline solid.
CAS:
196808-24-9
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light.
InChi:
InChI=1S/C30H29N3O4/c1-33(28-13-7-8-18-31-28)19-20-37-24-16-14-22(15-17-24)21-27(30(35)36)32-26-12-6-5-11-25(26)29(34)23-9-3-2-4-10-23/h2-18,27,32H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
InChiKey:
QTQMRBZOBKYXCG-MHZLTWQESA-N
Long Description:
Chemical. CAS: 196808-24-9. Formula: C30H29N3O4. MW: 495.6. Potent and subtype-selective (>1'000-fold) PPARgamma agonist. Angiogenesis inhibitor. Apoptosis inhibitor. Anti-inflammatory. Anti-hyperglycemic and anti-hyperlipidemic agent. Antidiabetic. The glucose-lowering effect in rats is 100-fold more potent than that of troglitazone.
MDL:
MFCD04040003
Molecular Formula:
C30H29N3O4
Molecular Weight:
495.6
Package Type:
Vial
Product Description:
Potent and subtype-selective (>1'000-fold) PPARgamma agonist [1]. Angiogenesis inhibitor [3]. Apoptosis inhibitor [4]. Anti-inflammatory [4]. Anti-hyperglycemic and anti-hyperlipidemic agent [1]. Antidiabetic. The glucose-lowering effect in rats is 100-fold more potent than that of troglitazone [2].
Purity:
>98% (HPLC)
SMILES:
COC1=CC(=O)OC(=C1)C1C2(O)CC3OC(=O)[C@]2(O)C(C(=O)C2=CC=CC=C2)C1(O)C3O
Solubility Chemicals:
Soluble in DMSO or methanol.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C. Store solutions at -20°C in the dark.
References
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents: B.R. Henke, et al.; J. Med. Chem. 41, 5020 (1998) | A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat: K.K. Brown, et al.; Diabetes 48, 1415 (1999) | PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium: E. Scoditti, et al.; Cardiovasc. Res. 86, 302 (2010) | Ameliorative Effects of GW1929, a Nonthiazolidinedione PPAR gamma Agonist, on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury: R.K. Kaundal & S.S. Sharma; Curr. Neurovasc. Res. 8, 236 (2011) | Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation: R. Tanaka, et al.; ESC Heart Fail. ahead of print (2020)
Related Products
| Product Name | Product Code | Supplier | Ciglitazone | AG-CR1-0033 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pioglitazone | AG-CR1-0067 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rosiglitazone | AG-CR1-3570 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rosiglitazone . maleate | AG-CR1-3571 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||